Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-3.84%
-4.02%
-5.95%
+5.45%
-4.41%
NVS
Novartis AG
$117.19
Chart
$116.7 (+0.42%)
$110.79 (+5.78%)
$112.87 (+3.83%)
$110.67 (+5.89%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-3.84%
-4.02%
-5.95%
+5.45%
-4.41%
NVS
Novartis AG
Current Price
$117.19
Login to view Novartis AG (NVS) recommendation from the last 90 days from financial news and social media.
Chart
$116.7 (+0.42%)
$110.79 (+5.78%)
$112.87 (+3.83%)
$110.67 (+5.89%)
NVS Latest Analysis
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies.
Thu Jul 24, 2025
Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight. Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity |. DelveInsight The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors as the increasing incidence of melanoma the launch of emerging therapies such as Lerapolturev (Istari Oncology) Nidlegy (Phi
Tue Jul 22, 2025
Novartis Sacrifices A Breakout As One Of Its Bread-And-Butter Drugs Misses. Novartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx one of its biggest moneymakers.The post Novartis Sacrifices A Breakout As One Of Its Bread-And-Butter Drugs Misses appeared first on Investor'.s Business Daily.
Thu Jul 17, 2025
Dementia Associated with Alzheimers Disease Drug Development Surges with 180 Companies Pushing New Therapeutic Frontiers | DelveInsight. Dementia Associated with Alzheimer'.s Disease Drug Development Surges with 180 Companies Pushing New Therapeutic Frontiers |. DelveInsightDementia associated with Alzheimer'.s disease is a progressive neurodegenerative condition characterized by memory loss cognitive decline and impaired daily functioning. The growing aging population worldwide is l
Thu Jul 17, 2025
Novartis Raises Operating Income Outlook After Strong Q2 Performance Initiates $10 Billion Stock Buyback (CORRECTED).
Thu Jul 17, 2025
Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price.
Thu Jul 17, 2025
Novartis Trims Operating Income Outlook After Strong Q2 Performance Initiates $10 Billion Stock Buyback. Swiss pharmaceutical giant ) reported second-quarter 2025 earnings on Thursday and raised its full-year earnings forecast.Quarterly sales reached $14.05 billion almost in line with the analysts’. consensus .Net sales 12% year over year (11% on constant currency or cc) with core operating income up 20% to $5.93 billion (21% on constant currency).Also Read: Sales growth driven by performa
Thu Jul 17, 2025
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise. Sales of breast cancer drug Kisqali grew 100% in the United States in the three months to June.
Thu Jul 17, 2025
Earnings Snapshot: Novartis International tops Q2 estimates. raises FY25 guidance for core operating income.
Thu Jul 17, 2025
Novartis launches up to $10 billion buyback lifts outlook.
Thu Jul 17, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings